skysight-inc/HackerNews huggingface dataset:
I once worked at a "hot" tech company that had a formal policy where HR had to get involved before rejecting a borderline candidate if they were female. It was a shame -- up until that point there were few female engineers but they were all brilliant. After that policy was implemented you had to wonder which were the token hires.
Yea, either one of those solutions would work just fine
Long story short, I first worked flex part-time (handing off time with my then spouse) when my kid was very young, then switched to being in an office when my kid started school and I was a single parent.

I went remote when my kid was in middle/high school because my kid needed me and it was good for me to be around. You can tell a 14 year old to shut up if you're on a conference call...most of the time. Also, I could take a few minutes in morning to get the kid to school (we lived close by to the school) or take a late lunch so my kid could go to after-school practices, classes, etc.

When a kid is in elementary school, it's vastly easier to work in an office. Elementary school is when life will be the most predictable with a kid. When a kid is in middle/high school, that's when you need to be present. For all the reasons you're thinking of. Teenagers are jerks.

All in all, I did pretty well. Kid is at a highly selective college these days.
Search while you play,
Always have a now playlist,
No ads (although this is a side effect of the implementation)
Different results display

Above all, it's an open source project that is also used to experiment and study
Simple Phonetic Generator
I have this impression in my mind that Gearbest is untrustworthy - this may have come from anecdotes where people were buying smaller ticket items where dishonesty, etc is more common, not sure. Anyways, I'm leery sending $800 to that site.
I think 5 minutes is an ideal target, and not a hard and fast rule, right? Otherwise how could you even go to the bathroom?
Full article is available here (it will show some loading page but the PDF should download immediately): https://www.researchgate.net/profile/Won_Bin_Young/publicati...
As a remote-working father of a 2-year-old, I agree with you. It's not perfect, but it's definitely better than being gone for 8+ hours per day.
While our population concentrates on the coast, IIRC on balance it still ends up being about a 50-50 split depending on how generously you want to define "coast". Also, the demographic trend is people moving towards coastal cities, so a large portion of current coastal city dwellers established their taste preferences growing up inland.

Geography is certainly a plausible component of the answer. But I personally think cultural norms are pretty arbitrary and self-sustaining; there doesn't need to be a deeper reason why "americans like beef" other than our parents did and that's what we grew up with (recurse N generations).
That theory would work except that if that were the case they would've bought him out and shut it down. Everyone wants to make money, as it stands someone will and they can be from any sort of background. Why hasn't a silicon valley head given this guy a few million though is beyond me.
It's just tricky because of the restrictions, and it's not just the restrictions themselves but the reality that you're limited to them in the future.

Even if your app can run in a sandbox today, are you willing to turn down any future feature requests that would make it so it won't?

We're putting an app on there, but our app is kind of an ideal use case because we don't expect to have to add features that can't work in the sandbox and our app is free. It's a tougher sell if you have to cut features to fit in the sandbox or hand off 30% of your sale to Apple.

Admittedly that 30% isn't unreasonable if you're really just starting out. That does include hosting, purchasing, and billing. But those things can be done at a much cheaper rate than 30% if you can set them up.

Panic is one of my favorite Mac app developers and (just checked) one of their apps (Coda) is distributed outside the App Store [1], while Transmit is distributed on both.

[1] https://panic.com/blog/coda-2-5-and-the-mac-app-store/
Thank you for sharing your story and putting up with these comments.

I just re-visited this thread a day later and didn't realize many of your points were not only shared by my comments in parallel, but also being re-requested by the same people.
They won't until you start demanding it, and walk away if you don't get what you ask for.
As I like to say, if nobody hates what you're doing, it isn't very interesting.
You listed remote here, but your job page says candidates that aren't based in SF are considered a consultant/contract gig--is that correct, or do you have FT remote positions available? Would love to chat if you do.
San Antonio Spurs | Basketball Information Systems Frontend Developer | Austin, TX | ONSITE, Full time, http://www.nba.com/spurs/

Help build a user friendly web based interface for use by the San Antoino Spurs Basketball Operations staff.

-Implement a web based front-end that responsively scales to function properly on desktop systems, tablets, and mobile devices.
-Design and develop data visualizations to be used in the basketball information system.
-Proactively maintain and support the basketball information system infrastructure.

If interested, please apply online at http://nbateamjobs.teamworkonline.com/teamwork/jobs/jobs.cfm...
Why do we call proposed Acts by the name their creators gave them, instead of choosing a more appropriate (and accurate) name?

"Internet freedom Act" - Empowering Telecom Companies Act

"SOPA" - Criminalize Ordinary Internet Behavior Act

"Patriot Act" - Remove Guaranteed Rights In Favor Of Empowering Central Authority Act

"Affordable Care Act" - Essentially Romneycare

etc. Why should these names not have colloquially adjudicated corrections applied to them the way anything else does?
Performance Monitoring for .NET Core
Might point him towards Propel(x) (https://www.propelx.com/). Its a newer syndicate model marketplace that focuses on "deep tech" investment. The team is knowledgable / motivated, and working to attract angels and institutional investors who understand these type of investments.
I'm guessing over the local network.
Considering your major is CS I think UIUC is the better choice, their STEM programs are much stronger than UVA's. I'm not sure the size and strength of the program help you that much when applying, but I think a good CS program will prepare you much better for a job (and interviews) in tech compared to somewhere like UVA.

That being said, I think they are both good choices. If you are sufficiently motivated there will be ample opportunities for whatever kind of tech entrepreneurship you have in mind at either school.
they said it was the thinnest lcd panel ever built. maybe the savings are in the top?
Here's a short interview clip from someone who lives alongside voices: https://twitter.com/BBCBreakfast/status/859351603131936768
No. Windows RT is not x86. It is ARM. Windows RT could never upgrade to regular Windows.
yes, but the minute you click a _second_ page, the Javascript app is already loaded, and we request only JSON for the new data.

Also this 4MB number isn't correct; I count 700kb. Feel free to double check my work:

http://imgur.com/a/gPiEb
In my experience they often seem averse to typing sales into a cash register, even when they have one right in from of them....or the ole "type the price in and hit "cash" " trick.

Must be some sort of a superstition.
I believe Windows RT could only run windows apps compiled for ARM, Windows S can run an x86 windows application
You're right. I don't have the resources for a full analysis but I did "shorten" three Google Maps links (IMO a good candidate for link shortening).

The compression for the three ranged between 114% and 117% of the original. E.g.:

https://www.google.ca/maps/place/Rockefeller+Center/@40.7586...

Encoded:

k:Yr5fL7YTHQz1AlBxKJrphUT0qAgf6ouSZ3Ze1yEQCNiTlmLclpycllFbllYTkxZcnJyY1hFTE0dUfkwV5SlgdREpEKLCUxjsWlLA6xpSJFMQx7EksQx6wsJCamsYViSIvoymS01Kch1NSlhIY2JOWYtyWWNESmNIbllYTkxZclpZRt
Not really explicitly, but implicitly they won't pay you to travel to conferences nobody has heard of (there was a list of acceptable conferences for the benefit at one point --- it covered pretty much all the well known conferences in our field, and there were a bunch of them).

Part of the idea is, the good conferences do some of the vetting for the bonus for you. They discourage "touring" talks, and have a high bar for inclusion, so if you're speaking at e.g. Black Hat, CanSecWest, Recon, and Toorcon, there's probably a reason that's happening and NCC is probably very happy about that reason.
Broadly, it's using an animal that is sufficiently like a human that it probably behaves similarly in whatever way is important for the study.

In practice they also often inbreed them to make them as identical as possible, and sometimes to induce specific changes. Ex: breeding mice that all get lung cancer would be an animal model of (human) lung cancer.

There are also transgenic models, where you might insert a human gene into a mouse to create a model of human disease, ex: inserting a huntingtin gene variant to induce Huntington's in mice and create a mouse model of Huntington's.
in search being the keyword

ads from paying businesses list higher than search results; this effectively means you pay to be "indexed" higher
This is the type of innovation we exchange for a sense of absolute security in having highly-vetted decade-long bio R&D and extensive backlogs at the FDA for approvals to sell products on the market. It's go big or go home because the regulatory risk/timeline is so extensive.

Most of these things die quietly or never get started so we never really see the true costs of what it takes to push the pharma world forward. It likely has a big effect on reinforcing existing monopolies as they are the only ones who can play that game (and pharma has been dominated by the same six companies since the 1800s). Usually R&D happens via a single trajectory which is either expensive internal labs at these companies or via anointed universities. There is very little variation on the source.

There's rarely an investment market between small scale seed stage and high growth phase. Which is where these bio R&D projects die.

Maybe there is an opportunity for a YC-style org to disrupt here. But I doubt it given the requirements to get to market.
This video is how I originally heard of CRISPR, and it's still the best video I have seen on the subject.
At schools in Poland. You can't have internet access so you won't look up answers on the internet. You have just computer in from of you. It's pretty standard way of doing any kind of grading.

Example would be for programming class or for office suite. You don't need internet to work in IDE or in Office.
From the abstract:

Intravenously injected quadruplex sgRNAs/saCas9 AAV-DJ/8
excised HIV-1 proviral DNA and significantly reduced
viral RNA expression in several organs/tissues of Tg26
mice. In EcoHIV acutely infected mice, intravenously
injected quadruplex sgRNAs/saCas9 AAV-DJ/8 reduced
systemic EcoHIV infection, as determined by live
bioluminescence imaging.

Can a mod change the title to reflect the findings? The original title is "In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models" and should be kept. That way maybe some people wouldn't just reflex-upvote and actually at least read the abstract...
Exactly. I've just started exploring dual numbers which are needed for automatic differentiation [0]. It's mind-blowing stuff, and it's easy to code in Lisp.

[0] https://en.m.wikipedia.org/wiki/Dual_number
The expensive part of getting a drug to market isn't proving that it can kill cells in a petri dish. Lots of stuff can do that, bleach, hydrogen peroxide...

The expensive part is the clinical trial. You try out the compound in the chemical woodchipper that is the human body, and see what happens. Almost all drugs fail at this point: http://blogs.sciencemag.org/pipeline/archives/2017/01/23/i-d...

>The timing of this report from the FDA is surely no accident, but it’s always a good time to think about this: the great majority of all drugs that enter clinical trials fail. They fail because they don’t do anyone any good, or because what good they might do is outweighed by some serious and unexpected harm. Around 90% of all compounds that start in the clinic never make it out. Even by the time you get to Phase III – and these are drugs that have apparently already worked in sick patients by that point – the failure rate is still nearly 40%. Drug projects fail constantly.

Nobody can predict if a drug will make it through the clinic, and if they say they can, they're lying. There's no way to model it, at all, it's just hugely computationally intractable.

And even if you make it through the first three formal phases of clinical trial, you can get bit in the "fourth" phase: regular patients buying it retail, and maybe dying at statistically higher rates. Consider the Vioxx debacle: https://en.wikipedia.org/wiki/Rofecoxib

>Rofecoxib /ˌrɒfᵻˈkɒksɪb/ is a nonsteroidal anti-inflammatory drug (NSAID) that has now been withdrawn over safety concerns. It was marketed by Merck & Co. to treat osteoarthritis, acute pain conditions, and dysmenorrhea. Rofecoxib was approved by the U.S. Food and Drug Administration (FDA) on May 20, 1999, and was marketed under the brand names Vioxx, Ceoxx, and Ceeoxx.

>On September 30, 2004, Merck withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use. Merck withdrew the drug after disclosures that it withheld information about rofecoxib's risks from doctors and patients for over five years, resulting in between 88,000 and 140,000 cases of serious heart disease.[2] Rofecoxib was one of the most widely used drugs ever to be withdrawn from the market. In the year before withdrawal, Merck had sales revenue of US$2.5 billion from Vioxx.[3] Merck reserved $970 million to pay for its Vioxx-related legal expenses through 2007, and has set aside $4.85bn for legal claims from US citizens.

VC's could spend hundreds of millions on clinical trials for DRACO, make it on the market... and only then discover that it gives patients incurable brain cancer 20 years after they take it.
Wow! For some reason, this blows my mind. I guess I had my mind a dozen people sitting in an office writing checks and compiling reports. I had no idea it was a huge global organization with 1420 employees and 8 locations around the world.

In retrospect, it makes such perfect sense that I feel foolish :)
>> 1 - All those parenthesis. (Still a top objection)

> If you actually count parens fairly you will find that Lisp has no more than any other language

Bull. For example, compare the Lisp factorial function from the article:

(define (fact x)
(if (zero? x)
1
(* x (fact (- x 1)))))

with the corresponding F# implementation:

let rec fact x =
if x = 0 then 1
else x * fact (x - 1)

That's 7 vs. 1 pair of parens.

Also, the problem isn't just that Lisp has so many parens, but that they nest so deeply and quickly. Five nested levels of parens for factorial alone.
Style transfer makes classic paintings look frighteningly close to photographs
Thimble.io | Marketing Director | Buffalo, NY | Onsite | Full time

What we do: Thimble teaches beginners the basics of building electronics by providing a monthly subscription kit and curated instructions. (Imagine building a new robot or quadcopter every month) We’ve built 16+ engaging kits, each with an intuitive web interface and video tutorials. Examples of projects include a WiFi-robot, LED cube, robotic arm, alarm clock, weather station, quadcopter, etc. You can find us at https://www.thimble.io.

Traction: We launched on Kickstarter during February ‘16, and raised just shy of $300,000 with close to 1,800 backers. And we delivered! :) We started shipping in December ‘16 and have been growing significantly every month since then. We are currently delivering our kits in all 50 states and 7 continents. (Our Kickstarter can be viewed here in case you're curious: http://kck.st/1QodNaL) Since Kickstarter, we've launched our own online store and have decent monthly recurring revenue.

As you might imagine, we've reached a pivotal point in our startup company and we're currently looking to hire someone to run our marketing department. This is an essential hire for us as this person will run the entire department (data-driven marketing/advertising: digital and traditional ad buys, earned media, interactive content and ad copy creation). We've been doing this ourselves but have been half-assing it and need someone who can own it and push us forward.

Qualifications:
--3-5 years experience in digital marketing across all disciplines with an emphasis on media buying, campaign tracking/optimization, content marketing and influencer marketing

--Being data-driven and kind of a data-geek; clear understanding of data, analytics, metrics and statistics

--Maker/DIY "I can do this" attitude or familiar with Maker Movement

--Being social and understanding users' behaviors. Having great customer relations skills

--Graphic/web design skills (comfortable with HTML/CSS, vector and raster graphics)

--A/B testing and data analytics experience

--Editing and copywriting skills

--Knowledge about both inbound and outbound marketing

--Being curious and creative

--Being relentless in pursuit of growth

--Willing to learn

If this sounds like something you might be interested in, please reach out to us at oscar at thimble dot io. We're three guys at the moment and looking for someone that wants to grow and be a part of something big and meaningful. Thanks in advance for reading! :-)
>> Maybe I'm getting this all wrong, but aren't the leaves also representing chunked data, which is compressed.

Leaf nodes contain data from one series (this data should be read together) and SSTable with time-series data contains many series and there is no guarantee that all these series will be used by the query.

>> The Prometheus solution also sequentially places compressed chunks for the same series.

I'm not really that familiar with Prometheus internals, especially with indexing part. As I understand it doesn't align writes so there is a lot of write amplification on the lower level that translates to cell degradation and non-optimal performance, but I can be wrong here.
I had a hard time sorting out your meaning, but adding NP to the mix is delicious so I can't resist replying, and I hope I get it right.

I take it you mean something like this:
In the real world, NP hard problems are "solved" by approximations; and the range in the accuracy (and speed) of various possible approximation algorithms is immense in many or most cases. Which means you want your best woman doing the job, 'cause she's easily ten times better than the next man up, in fact her final algorithm might be thousands of times better and faster than her previous try last week and yet still leave a crazy amount of room for improvement, one day.
Model of a zombie outbreak with Python
It doesn't work like that. Companies have already tried (see: Google Contributor) with very limited success. The reality is that you're heavily in the minority of people who care about tracking and privacy and ads. There's no market for it, and the largest analogous service, YouTube Red, explicitly needs to offer exclusive content and access to streaming media just to entice people.
Using Lisp (in the form of Racket) for many years in a production environment, I've observed:

1. People do complain about the parentheses but they generally get to work dealing with them right away. It's the loudest complaint, but it doesn't really even slow people down.

2. This is a similar complaint, and does scare people off from jumping in if they have a real choice.

3. Racket in particular solves this one to an extent. We've used it with Redis, JSON, MySQL, Perforce, etc etc productively. More commentary below, though...

4. This one is a non-issue as far as I've seen. If you hire someone who can program, then can quickly learn and be productive in Lisp.

5. This is tied in with 4, a non-issue.

6. This is an issue with perception. The problem is more that people believe they know something about Lisp because they've heard of it, and they come in with the expectation that it'll be weird or difficult, which is a bit of a speed bump to getting to work right away.

Ultimately the biggest issue we've seen is that the broader ecosystem of organizations using Lisp (or Racket) in production environments is missing. As such, there are many sharp corners that you have to file off yourself as you deploy your usage. Useful resources like Stack Overflow just don't have the answers prepackaged because it's likely you're the first to use Perforce to deploy a precompiled version of your Racket application on Windows (for example).

It's easy to underestimate just how much work people have put into making ecosystems in C++, Java, and Python contain all the pieces, experience, and knowledge you'll need to solve your particular problems quickly and effectively.

Another pieced missing along with that ecosystem: outside of the implementation of the language itself, no one has taken an application of significant size and age and added a major feature to it. This is something that happens in production all the time -- and it happens on a schedule with a budget. Virtually no one using a small or academically minded languages ever does this, though. And it's not until you try that do you discover all those sharp corners and missing support tools and libraries.
Well, as CRISPR was originally found as a kind of immune system, there do exist a number of anti-anti-Cas9 systems against that evolved alongside it. There are a number of small inhibitors of Cas9 [1] (which themselves could be used to tune Cas9 in therapeutics). However up-taking such a defense is admittedly an unlike route for a virus like HIV to take to evolve resistance to a CRISPR-based therapy.

More practically, HIV has such a high mutation rate, that it's likely very difficult to target every HIV sequence with a sequence-specific Cas9 therapy. If the Cas9 guide sequence is too generic it'll take out stuff besides HIV (stuff you need). And if the guide sequence is too specific it won't get all the viral inserts because many are degenerate. As with all things though, 95% success with viral excision via CRISPR, in conjunction with 95% success via immunotherapy [2], and 95% from standard anti-retrovirals [3], get's you pretty good 99.9999% coverage.

That's the power of convergent technologies. It's an interesting slice through a number of modern therapeutic technologies all applied to one of the most challenging of tailored foes. You see convergence of small molecule biochemistry along with immunotherapy, along gene therapy, along with cutting edge synthetic biology - all approaching the problem from different angles.

[1] www.cell.com/cell/fulltext/S0092-8674(16)31683-X

[2] https://serotiny.bio/notes/proteins/ecd4ig/

[3] https://en.wikipedia.org/wiki/Category:Antiretroviral_drugs
It's literally capitalism at work.

The market at work, surely.